Attention Investors : Prevent Unauthorized Transactions in your Trading / demat account -->Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. Update your Mobile Number & e mail id with your Broker / Depository Participant. Receive alerts on your Registered Mobile for all Transactions / debit and other important transactions in your Trading / demat account directly from Exchanges & CDSL on the same day. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month......... Issued in the interest of investors. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. SCORES - Filing compliant on SCORES – Easy & quick    a. Register on SCORES portal.    b. Mandatory details for filing complaints on SCORES : Name, PAN, Address, Mobile Number, Email ID.    c. Benefits : Effective communication . Speedy redressal of the grievances Website : https://scores.sebi.gov.in/ Head Office / ARN Desk Backoffice Employee Sub-Broker/Sale Manager Branch Client Quotes NAV Insurance NAV

ipo  IPO Forthcoming IPO's Open / Current IPO's Closed IPO's New Issue Monitor New Listing Basis of Allotment Draft Prospectus Best Performers IPO News Know IPO's / FAQ's Equities | Mutual Funds | Commodities | Derivatives | IPO | Insurance Products & Services    >   IPO   >   Synopsis Details Sudeep Pharma Ltd Registered Office:    129/1/A GIDC Estate Nandesari ,   ,   Vadodara - 391340 ,   Gujarat , India.   Phone: +91 265 284 0656/329 1354   Fax: cs.sudeep@sudeepgroup.com   Website:https://www.sudeeppharma.com Initial public offer of up to [*] equity shares of face value of Re. 1/- each ("Equity Shares") of Sudeep Pharma Limited ("Company") for cash at a price of Rs. [*] per equity share (Including a Share Premium of Rs. [*] per Equity Share) ("Offer Price") aggregating up to Rs. [*] crores comprising a fresh issue of up to [*] equity shares of face value of Re. 1/- aggregating up to Rs. 95.00 crores by the company ("Fresh Issue") and an offer for sale of up to 13,490,726 equity shares of face value of Re. 1/- aggregating up to Rs. [*] crores ("Offered Shares") by the selling shareholders, consisting of up to 3,567,670 equity shares of face value of Re. 1/- aggregating up to Rs. [*] crores by Sujit Jaysukh Bhayani*, up to 8,418,856 equity shares of face value of Re. 1/- aggregating up to Rs. [*] crores by Sujeet Jaysukh Bhayani HUF, up to 750,000 equity shares of face value of Re. 1/- aggregating up to Rs. [*] crores by Shanil Sujit Bhayani** and up to 754,200 equity shares of face value of Re.1/- aggregating up to Rs.[*] crores by Avani Sujit Bhayani** (Collectively "the Selling Shareholders") and such equity shares offered by the selling shareholders ("Offer for Sale", and together with the fresh issue, the "Offer"). The company, in consultation with the brlms, may consider an issue of specified securities aggregating up to Rs. 19.00 crores, as may be permitted under applicable law, prior to filing of the ("pre-ipo placement"). The pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the brlms. If the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) Rules, 1957, as amended. The pre-ipo placement, if undertaken, shall not exceed 20% of the size of the fresh issue. Prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the offer or the offer may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if undertaken). The face value of equity shares is Re. 1/- each. the offer price is [*] times the face value of the equity shares. Price Band: Rs. 563 to Rs. 593 per equity share of face value of Rs. 1 each. The floor price is 563 times the face value of the equity shares and the cap price is 593 times the face value of the equity shares. Bids can be made for a minimum of 25 equity shares and in multiples of 25 equity shares thereafter. Issue Money Payable On Opens On Closes On Application Allotment 21-Nov-25 25-Nov-25 Rs 563.00-593.00 Rs 0.00-0.00 Minimum Application for shares in Nos : 25   Further Multiples of : 25 Sudeep Pharma Ltd   Rs Cr Lead Managers to the Issue Project Cost 0.00 ICICI Securities Limited IIFL Capital Services Limited Project Financed through Current Offer 854.53   Post Issue Equity Share Capital 11.29   Issue Price Rs. 563.00   Projects Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I General corporate purposes Promoted By Sujit Jaysukh Bhayani Avani Sujit Bhayani Shanil Sujit Bhayani Listing At BSE NSE Registrar to the Issue                SEBI Common Reg. No. INZ000206338          MAPIN NO:10014845        CDSL : IN-DP-CDSL-291-2005 MERCHANT BANKING REGISTRATION NO : NM000011575 Terms of the Site   I   Privacy Policy   I  Disclaimer   I  Broker Norms   I  Attention and Advisory for Investors   I  Investor Relations   I  Investor Charter   I  Site Map   I  Payment Gateway   I  Circular   I  Upfront Margin   I  Pricing   I  Investor Complaints   I  Depository Participant   I  Investor Complaints for DP   I  CDSL E-Voting   I  Maintenance of Website   I   Details of authorized persons   I   SMART ODR   I   Bank Details   I   View Client Collateral Details   I   Online KYC Closure INTERNAL CONTROL POLICY  I  AML POLICY  I  RMS POLICY  I  POLICIES & PROCEDURES  I  CLIENT ACCEPTANCE POLICY   I   CLIENT REGISTRATION FORM KYC Form Mandatory Document   I   DOCUMENTS IN VERNACULAR LANGUAGES BSE  I  NSE  I  CDSL  I  SEBI  I  MCX  I  NCDEX © 2010 SHARE MART. All rights reserved Designed, Developed and Content provided by CMOTS Infotech ( ISO 9001:2015 certified )